NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
April 08, 2024 07:00 ET
|
NextCure
BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
April 04, 2024 07:05 ET
|
NextCure
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 07:00 ET
|
NextCure
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
March 21, 2024 08:55 ET
|
NextCure
Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts...
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
March 05, 2024 08:05 ET
|
NextCure
BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
January 18, 2024 16:05 ET
|
NextCure
BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
December 21, 2023 07:05 ET
|
NextCure
BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Provides Year-End Clinical Pipeline Updates
December 14, 2023 06:45 ET
|
NextCure
BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023 07:00 ET
|
NextCure
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
November 15, 2023 16:05 ET
|
NextCure
New publication in Journal of Clinical Investigation provides compelling evidence for NC525’s ability to specifically kill leukemic cells while sparing healthy cells in non-clinical modelingUpdate for...